Stocks
News
ETFs
Economy
Currencies
Press Releases
Innate Pharma S.A. - American Depositary Shares (IPHA)
Last Price
2.1600
Change
-0.1600 (-6.90%)
NASDAQ
· Last Trade: May 13th, 1:27 PM EDT
Quote
News
Press Releases
Chart
Historical
FAQ
About
Competitors
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 13, 2025
Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 12, 2025
Innate Pharma announces conference call and webcast for Q1 2025 business update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· May 6, 2025
Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 30, 2025
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 29, 2025
Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 28, 2025
Innate Pharma Announces €15M Investment by Sanofi
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 24, 2025
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 23, 2025
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 16, 2025
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 16, 2025
Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· April 3, 2025
Innate Pharma Reports Full Year 2024 Financial Results and Business Update
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 27, 2025
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 26, 2025
Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 25, 2025
Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· March 20, 2025
Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· February 27, 2025
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· February 17, 2025
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 27, 2025
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 21, 2025
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 16, 2025
Innate Pharma Announces Transformative Strategy to Accelerate Growth
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· January 10, 2025
Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· December 20, 2024
Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· December 9, 2024
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· December 6, 2024
Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024
Regulatory News:
By
Innate Pharma SA
· Via
Business Wire
· December 3, 2024
